IB-T101 not checked

Grit Biotechnology

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“IB-T101 injection to treat advanced clear renal cell carcinoma”In the company’s words, NCT06819293 on ClinicalTrials.gov
Tested for
Advanced Clear Renal Cell Carcinoma, Adult
Main trialPhase 1
“This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma”In the company’s words, NCT06819293 on ClinicalTrials.gov

Other drugs for Adult

All 126 drugs for Adult

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 7 Dec 2027 IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IB-T101

Following is part of Solo: you see every change to IB-T101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in